Perrigo Co PLC
PRGO
Company Profile
Business description
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm’s product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Contact
The Sharp Building
Hogan Place
DublinD02 TY74
IRLT: +353 17094000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
8,379
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.40 | 22.00 | -0.24% |
| CAC 40 | 7,874.89 | 24.46 | 0.31% |
| DAX 40 | 24,465.87 | 225.05 | 0.93% |
| Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
| FTSE 100 | 9,109.50 | 48.01 | 0.53% |
| HKSE | 25,633.29 | 95.22 | 0.37% |
| NASDAQ | 21,020.02 | 127.33 | 0.61% |
| Nikkei 225 | 41,826.34 | 655.02 | 1.59% |
| NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
| S&P 500 | 6,358.91 | 49.29 | 0.78% |
| S&P/ASX 200 | 8,709.40 | 27.80 | -0.32% |
| SSE Composite Index | 3,605.73 | 23.43 | 0.65% |